These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cholera toxin as a mucosal adjuvant: III. Antibody responses to nontarget dietary antigens are not increased. Nedrud JG; Sigmund N Reg Immunol; 1990-1991; 3(5):217-22. PubMed ID: 1966580 [TBL] [Abstract][Full Text] [Related]
5. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802 [TBL] [Abstract][Full Text] [Related]
6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Strindelius L; Filler M; Sjöholm I Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861 [TBL] [Abstract][Full Text] [Related]
8. Transport of serum IgA into murine respiratory secretions and its implications for immunization strategies. Mazanec MB; Nedrud JG; Liang XP; Lamm ME J Immunol; 1989 Jun; 142(12):4275-81. PubMed ID: 2542407 [TBL] [Abstract][Full Text] [Related]
9. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723 [TBL] [Abstract][Full Text] [Related]
10. Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization. Vajdy M; Lycke N Immunology; 1995 Nov; 86(3):336-42. PubMed ID: 8550068 [TBL] [Abstract][Full Text] [Related]
11. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Oien NL; Brideau RJ; Walsh EE; Wathen MW Vaccine; 1994 Jun; 12(8):731-5. PubMed ID: 8091852 [TBL] [Abstract][Full Text] [Related]
12. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076 [TBL] [Abstract][Full Text] [Related]
13. Immunodulation of rat serum and mucosal antibody responses to Entamoeba histolytica trophozoites by beta-1,3-glucan and cholera toxin. Navarro-García F; Pedroso M; López-Revilla R Clin Immunol; 2000 Nov; 97(2):182-8. PubMed ID: 11027459 [TBL] [Abstract][Full Text] [Related]
14. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859 [TBL] [Abstract][Full Text] [Related]
15. Oral immunization with Sendai virus in mice. Nedrud JG; Liang XP; Lamm ME Curr Top Microbiol Immunol; 1989; 146():117-22. PubMed ID: 2543541 [TBL] [Abstract][Full Text] [Related]
16. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Nyström-Asklin J; Adamsson J; Harandi AM Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617 [TBL] [Abstract][Full Text] [Related]
17. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461 [TBL] [Abstract][Full Text] [Related]
18. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Tamura SI; Kurata T Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706 [TBL] [Abstract][Full Text] [Related]